NDC 51224-153-12 - Aluminum Acetate Astringent
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 51224-153
- Requested NDC
- 51224-153-12
- Package NDCs from labels
- 51224-153-99, 51224-153-12, 51224-153-24
- Manufacturer
- TAGI Pharma Incorporated
- Effective date
- 2018-11-20
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Aluminum Acetate Astringent - TAGI Pharma Incorporated | TAGI Pharma Incorporated | 2018-11-20 | HUMAN OTC DRUG LABEL |
| National Council for Prescription Drug Programs indexing - billing unit | National Council for Prescription Drug Programs | 2012-07-24 | Indexing - Billing Unit |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 51224-153-12 | EA - Each | 51224-153 | 5d44d708-f3d0-4fce-a247-43c5e59de299 | 1 | 2012-07-24 |
| 51224-153-24 | EA - Each | 51224-153 | ddadcdbf-7122-439a-a34f-4b489cf5f0f1 | 1 | 2012-07-24 |
| 51224-153-99 | EA - Each | 51224-153 | cac4fea4-7db4-455e-b348-f2ee4916b3a1 | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| Aluminum sulfate | ACTIVE INGREDIENT | 34S289N54E | ALUMINUM ACETATE ASTRINGENT (CALCIUM ACETATE AND ALUMINUM SULFATE) POWDER, FOR SOLUTION [TAGI PHARMA INCORPORATED] | 1 | |
| Calcium Acetate | ACTIVE INGREDIENT | Y882YXF34X | ALUMINUM ACETATE ASTRINGENT (CALCIUM ACETATE AND ALUMINUM SULFATE) POWDER, FOR SOLUTION [TAGI PHARMA INCORPORATED] | 1 | |
| Aluminum Cation | ACTIVE MOIETY | 3XHB1D032B | ALUMINUM ACETATE ASTRINGENT (CALCIUM ACETATE AND ALUMINUM SULFATE) POWDER, FOR SOLUTION [TAGI PHARMA INCORPORATED] | 1 | |
| Calcium Cation | ACTIVE MOIETY | 2M83C4R6ZB | ALUMINUM ACETATE ASTRINGENT (CALCIUM ACETATE AND ALUMINUM SULFATE) POWDER, FOR SOLUTION [TAGI PHARMA INCORPORATED] | 1 | |
| icodextrin | INACTIVE INGREDIENT | 2NX48Z0A9G | ALUMINUM ACETATE ASTRINGENT (CALCIUM ACETATE AND ALUMINUM SULFATE) POWDER, FOR SOLUTION [TAGI PHARMA INCORPORATED] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Calcium Acetate | CALCIUM ACETATE | American Health Packaging | 2072d9f4-abb1-4699-bde5-6041dd79cad5 | 2026-09-04 | Warnings, Adverse reactions | Y882YXF34X |
| calcium acetate | CALCIUM ACETATE | REMEDYREPACK INC. | 89a2ee04-1024-4a81-ba0d-a6655d529827 | 2026-09-03 | Warnings, Adverse reactions | Y882YXF34X |
| Calcium Acetate | CALCIUM ACETATE | AvPAK | 52e35dd6-db95-98e6-e063-6294a90ab801 | 2026-05-28 | Warnings, Adverse reactions | Y882YXF34X |
| Calcium Acetate | CALCIUM ACETATE | Rising Pharma Holdings, Inc. | ce650ba5-fb42-e444-e053-2a95a90a075a | 2026-05-15 | Warnings, Adverse reactions | Y882YXF34X |
| Calcium Acetate | CALCIUM ACETATE | NCS HealthCare of KY, LLC dba Vangard Labs | 7177829c-bd89-485c-b5e3-15e457e969c5 | 2026-04-17 | Warnings, Adverse reactions | Y882YXF34X |
| Calcium Acetate | CALCIUM ACETATE | Cardinal Health 107, LLC | a23b6070-eb4b-48e3-b563-8232206a6be4 | 2026-04-15 | Warnings, Adverse reactions | Y882YXF34X |
| Calcium Acetate | CALCIUM ACETATE | Major Pharmaceuticals | 9a731cdf-6488-44ca-b97f-512a0e9deab1 | 2026-03-17 | Warnings, Adverse reactions | Y882YXF34X |
| Calcium Acetate | CALCIUM ACETATE | Westminster Pharmaceuticals, LLC | 1195f5d5-db91-4b9e-86ad-be340b43d690 | 2026-02-24 | Warnings, Adverse reactions | Y882YXF34X |
| Calcium Acetate | CALCIUM ACETATE | American Health Packaging | 1090762c-eec1-4ab0-9ddc-43caa764cd0e | 2026-01-08 | Warnings, Adverse reactions | Y882YXF34X |
| THY-Plex | THYROID SUPPORT | Vitality Works, Inc. | deea70d1-5175-4c7e-ae69-dd48ff212f08 | 2025-12-17 | Warnings | Y882YXF34X |
| Calcium Acetate | CALCIUM ACETATE | PD-Rx Pharmaceuticals, Inc. | 925918d5-9f89-4f2f-9bb9-d9c53d90bb0a | 2025-10-14 | Warnings, Adverse reactions | Y882YXF34X |
| calcium acetate | CALCIUM ACETATE | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | d48c66a9-26fe-4e1a-a68a-88afe83fb51d | 2025-07-01 | Warnings, Adverse reactions | Y882YXF34X |
| EXTRANEAL | ICODEXTRIN, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE | Vantive US Healthcare LLC | d5b85158-b0d6-4855-9d07-8d1b3ad9ab71 | 2025-06-30 | Warnings, Adverse reactions | 2NX48Z0A9G |
| calcium acetate | CALCIUM ACETATE | AvKARE | 35a6f515-dfe7-031c-e063-6294a90a5e95 | 2025-06-04 | Warnings, Adverse reactions | Y882YXF34X |
| Calcium Acetate | CALCIUM ACETATE | Proficient Rx LP | 80c15366-9420-41c2-8817-b9c39ddfcec1 | 2025-06-01 | Warnings, Adverse reactions | Y882YXF34X |
| EXTRANEAL | ICODEXTRIN, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE | Vantive US Healthcare LLC | 5bf31b49-24c8-4021-98da-33a151f2fcbe | 2025-05-08 | 2NX48Z0A9G | |
| EXTRANEAL | ICODEXTRIN, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE | Vantive US Healthcare LLC | e18bacfe-af60-49dc-bd30-cb3c29fa16db | 2025-05-07 | 2NX48Z0A9G | |
| EXTRANEAL | ICODEXTRIN, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE | Vantive US Healthcare LLC | 2b327b13-a0e9-4b2c-9875-4470998e2e30 | 2025-05-07 | 2NX48Z0A9G | |
| Calcium Acetate | CALCIUM ACETATE | Hikma Pharmaceuticals USA Inc. | 85fd41f8-2823-44ca-a15e-f1f2e5d0ff94 | 2025-04-17 | Warnings, Adverse reactions | Y882YXF34X |
| Aluminium sulphuricum | ALUMINIUM SULPHURICUM | Hahnemann Laboratories, Inc. | a474ba15-34a5-f07e-e053-2995a90a61ca | 2025-01-09 | 34S289N54E |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.